biostudies-literatureUnknown21(11)Ritchie DSIn a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3 × 109 total T cells, of which 14-38% expressed the CAR. Grade 3 or 4 toxicity was not observed. One patient achieved a cytogenetic remission whereas another with active leukemia had a reduction in peripheral blood (PB) blasts and a third showed a protracted remission. Using an aliquot of In111-labeled CAR T cells, we demonstrated trafficking to the bone marrow (BM) in those patients with the greatest clinical benefit. Furthermore, in a patient with leukemia cutis, CAR T cells infiltrated proven sites ofMolecular therapy : the journal of the American Society of Gene Therapy2122-9https://www.ebi.ac.uk/biostudies/studies/S-EPMC3831035biostudies-literaturePersistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.PMC3831035Peinert SScott AMHonemann DChen KKravets LKershaw MHRitchie DSNeeson PJWestwood JAKhot AShin MTrapani JATainton KDarcy PKPrince HMDickinson MGambell PWall DMTai TWesterman DAHaurat JSmyth MJfalsePersistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3 × 109 total T cells, of which 14-38% expressed the CAR. Grade 3 or 4 toxicity was not observed. One patient achieved a cytogenetic remission whereas another with active leukemia had a reduction in peripheral blood (PB) blasts and a third showed a protracted remission. Using an aliquot of In111-labeled CAR T cells, we demonstrated trafficking to the bone marrow (BM) in those patients with the greatest clinical benefit. Furthermore, in a patient with leukemia cutis, CAR T cells infiltrated proven sites of2013-01-01T00:00:00Z2013 Nov2026-05-07T01:34:03.793Z2026-04-07T22:27:53.393ZS-EPMC38310352383159510.1038/mt.2013.154